Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Aino Co., Ltd. of North China Pharmaceutical Group
WARNING LETTER
•Aino Co., Ltd. of North China Pharmaceutical Group•December 14, 2012

Aino Co., Ltd. of North China Pharmaceutical Group – FDA Warning Letter, Dec 14, 2012

Record Details

The FDA issued a Warning Letter to Aino Co., Ltd. of North China Pharmaceutical Group on August 30, 2012, due to failure to fulfill drug establishment registration obligations. The company continued to manufacture and import drugs into the U.S. in 2011 and 2012 without annual registration, a violation of Section 510(i)(1) and 301(p) of the Federal Food, Drug, and Cosmetic Act (the Act).

The FDA had previously notified Aino Co., Ltd. on October 11, 2011, about their unregistered status. Unregistered establishments and unlisted drugs are subject to refusal of admission under Section 801(o) and 801(a)(3) of the Act, and drugs may be deemed misbranded under Section 502(o) if not properly listed per 21 CFR Part 207.

Aino Co., Ltd. was required to immediately register their establishment and properly list all drugs offered for import. They were given fifteen working days to notify the FDA in writing of corrective actions taken, or provide a reason for delay and a new completion date. Failure to comply could result in refusal of drug imports and notification to importers/consignees. The FDA emphasized that registration and listing must now be submitted electronically via Structured Product Labeling (SPL).

Company
Aino Co., Ltd. of North China Pharmaceutical Group
Inspection date
December 14, 2012
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Douglas Stearn
View Company Profile

ID · 914d6ace-5d91-405b-ae12-cf0092b2c223

Violation Codes10
21 U.S.C. 360(i)(1)21 U.S.C. 331(p)21 CFR 207.40(b)21 U.S.C. 381(o)21 U.S.C. 360(i)21 U.S.C. 381(a)(3)21 U.S.C. 352(o)21 CFR 207.30(a)21 CFR 207.25(b)(7)21 U.S.C. 360(j)(2)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Aino Co., Ltd. of North China Pharmaceutical Group
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.